Researchers mapped how potent DPP-IV inhibitory peptides are released from tilapia skin collagen, finding that a specific enzyme (proteaC) produced the most active hydrolysate with an IC50 of 0.58 mg/mL.
IC50 = 0.58 mg/mLThe proteaC-digested collagen hydrolysate achieved this level of DPP-IV inhibitory potency — the strongest among all enzymes tested.
What the researchers found
ProteaC-digested collagen hydrolysate showed the highest DPP-IV inhibitory activity with an IC50 of 0.58 ± 0.02 mg/mL. The enzyme preferentially cleaved at glycine and hydrophobic amino acid residues at the P1' position and showed strong preference for hydroxyproline at the P1 position. Large amounts of Gly-Pro-type peptides consisting of 4, 6, and 9 amino acids were released. The dynamic release followed a clear pattern: precursor peptides → target active peptides → shorter peptides.
Why it matters
DPP-IV inhibitors are a major class of diabetes medications. Understanding how natural DPP-IV inhibitory peptides are released from food proteins like collagen could lead to functional foods or nutraceuticals that help manage blood sugar. This study provides the mechanistic blueprint for optimizing that release process.
How the study worked
Researchers used tilapia skin collagen as a starting material and tested multiple proteases to determine which released the most potent DPP-IV inhibitory peptides. They analyzed cleavage selectivity of each enzyme and tracked the dynamic release mechanism of Gly-Pro-type peptides over the course of digestion. DPP-IV inhibitory activity was measured using IC50 values.
What this study cannot tell us
This is an in vitro biochemistry study — the DPP-IV inhibitory activity was measured in a test tube, not in living organisms. Whether these peptides survive further digestion in the human gut, get absorbed intact, and reach effective concentrations in the bloodstream is unknown. The IC50 value represents enzyme inhibition in isolation, not a clinical blood sugar effect.
How to read the evidence
This is a preclinical laboratory study characterizing enzyme kinetics and peptide release patterns in vitro. While methodologically rigorous for its scope, it provides no evidence of efficacy in animals or humans.
When this study was published
Published in 2025, this is a very recent study reflecting ongoing research into food-derived bioactive peptides.
The bigger picture
There is growing interest in food-derived bioactive peptides as natural alternatives or complements to pharmaceutical DPP-IV inhibitors for blood sugar management. This work advances the understanding of how to efficiently produce these peptides from an abundant and sustainable source — fish processing waste. It bridges food science and peptide therapeutics.
Questions still open
- Do these fish collagen-derived DPP-IV inhibitory peptides survive human gastrointestinal digestion and reach the bloodstream?
- How does the DPP-IV inhibitory potency of these food-derived peptides compare to pharmaceutical DPP-IV inhibitors like sitagliptin?
- Could optimized fish collagen hydrolysates serve as functional food ingredients for blood sugar management?
Common questions
What are DPP-IV inhibitory peptides and why do they matter?
Can eating fish collagen help with blood sugar control?
Read the original research
Release pattern of potent dipeptidyl peptidase IV(DPP-IV) inhibitory peptides from tilapia (Oreochromis niloticus) skin collagen.
Food chemistry, 489, 144970
Citation
Li, Jiaxin; Yang, Danyin; Xu, Qiongyao; Huang, Mingtao; Zheng, Lin; Zhao, Mouming. (2025). Release pattern of potent dipeptidyl peptidase IV(DPP-IV) inhibitory peptides from tilapia (Oreochromis niloticus) skin collagen.. Food chemistry, 489, 144970. https://doi.org/10.1016/j.foodchem.2025.144970